We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Role of Nicotinic Acid in Atherosclerosis Prevention

Thomas F. Whayne Jr, MD, PhD1
[+] Author Affiliations
1Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington
JAMA Intern Med. 2014;174(4):648-649. doi:10.1001/jamainternmed.2013.12651.
Text Size: A A A
Published online


To the Editor Jackevicius et al1 recently published concerns that nicotinic acid use in the United States, especially extended-release niacin (Niaspan; AbbVie Inc), exceeds almost 6-fold of that in Canada. Their economic comparison and implied excess use was stimulated by the AIM-HIGH (the Atherothrombosis Intervention in Metabolic syndrome with low HDL [high-density lipoprotein]/high triglycerides: Impact on Global Health outcomes) and HPS-2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events) studies. The AIM-HIGH study reported that in patients with atherosclerotic cardiovascular disease (CVD) already treated with a statin to a low-density lipoprotein cholesterol (LDL-C) level of 71 mg/dL (to convert to millimoles per liter, multiply by 0.0259), no incremental benefit occurred with the addition of nicotinic acid to a statin therapy over 36 months. In HPS-2 THRIVE (starting LDL-C level of 63 mg/dL), nicotinic acid, combined with the antiflushing agent laropiprant, did not decrease CVD risk further in the presence of statin therapy.1 Both studies involved patients with proven CVD receiving statin therapy and essentially at the LDL-C target for high–CVD risk patients (<70 mg/dL). Showing significant benefit when already at the desired LDL-C target is problematic. Nevertheless, such results must be analyzed and answered.1


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





April 1, 2014
Cynthia A. Jackevicius, BScPhm, PharmD, MSc, BCPS; Harlan M. Krumholz, MD, SM
1Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, California2Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada3Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada4Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California5University Health Network, Toronto, Canada
6Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut7Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut8Department of Epidemiology and Public Health, Section of Health Policy and Administration, New Haven, Connecticut9Robert Wood Johnson Clinical Scholars Program, New Haven, Connecticut
JAMA Intern Med. 2014;174(4):649. doi:10.1001/jamainternmed.2013.12811.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...